Meeting
2020 ASCO Virtual Scientific Program
A phase II study of vorolanib (CM082) in combination with toripalimab (JS001) in patients with advanced mucosal melanoma.
Authors
Lu Si
Department of Renal Cancer & Melanoma, Peking University Cancer Hospital and Institute, Beijing, China
Lu Si , Xinan Sheng , Lili Mao , Caili Li , Xuan Wang , Xue Bai , Zhong Hui Qi , Zhihong Chi , Chuanliang Cui , BIN LIAN , Bixia Tang , Xieqiao Yan , Li Zhou , Siming Li , Rong Duan , Huayan Xu , Li Mao , Lieming Ding , Jun Guo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03602547
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10040)
DOI
10.1200/JCO.2020.38.15_suppl.10040
Abstract #
10040
Poster Bd #
389
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
First Author: Lu Si
Poster
2023 ASCO Annual Meeting
A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer.
First Author: Guangwen Yuan
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of anlotinib with or without PD-1 blockades in the treatment of advanced primary hepatocellular carcinoma (HCC): A real-world exploratory study.
First Author: Xiao-Qi Chen